Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02689063 · ClinicalTrials.gov registry record · Phase 3

Maxigesic IV Phase 3 Bunionectomy Study

A Phase 3 study of Post Operative Pain, sponsored by AFT Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
276
Enrollment target
2
Study locations

NCT02689063 is a Phase 3 study of Post Operative Pain that has completed, run by AFT Pharmaceuticals. The registered enrollment target is 276 participants, above the 232-participant average among 56 other Post Operative Pain trials with a reported enrollment target (19% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02689063, a Phase 3 study of Post Operative Pain, has completed, sponsored by AFT Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
276 participants
Enrollment target
2
Study locations

Study Summary

The purpose of the study is to determine the clinical efficacy and safety of Maxigesic IV, acetaminophen IV, Ibuprofen IV versus placebo IV for the treatment of acute postoperative pain after bunionectomy

Conditions Studied

Interventions

  • DRUG Placebo IV
  • DRUG IV Acetaminophen
  • DRUG IV Ibuprofen
  • DRUG Maxigesic IV

Study Locations (2)

Maryland

  • Chesapeake Reserach Group - Pasadena

Texas

  • Optimal Research - Austin

Trial Details

FieldValue
Enrollment Target 276 participants
Start Date 2016-10-26
Est. Completion 2017-09-15
Phase Phase 3

Sponsor

AFT Pharmaceuticals

6 total trials

What the Registry Record Tells You About NCT02689063

The ClinicalTrials.gov registry entry for NCT02689063 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 232-participant average among 56 other Post Operative Pain trials with a reported enrollment target (19% higher). The listed sponsor is AFT Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Post Operative Pain appearing as the primary indexed condition, and to 4 interventions - of which Placebo IV is the first listed.

NCT02689063 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Texas.

Frequently Asked Questions

What is clinical trial NCT02689063 about?

NCT02689063 is a clinical study titled "Maxigesic IV Phase 3 Bunionectomy Study". The purpose of the study is to determine the clinical efficacy and safety of Maxigesic IV, acetaminophen IV, Ibuprofen IV versus placebo IV for the treatment of acute postoperative pain after bunionectomy

What is the current status of trial NCT02689063?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2016-10-26. Estimated completion is 2017-09-15.

What conditions does trial NCT02689063 study?

This clinical trial studies the following conditions: Post Operative Pain.

What interventions are being tested in trial NCT02689063?

The interventions under investigation include: Placebo IV (DRUG), IV Acetaminophen (DRUG), IV Ibuprofen (DRUG), Maxigesic IV (DRUG).

Who is sponsoring clinical trial NCT02689063?

This trial is sponsored by AFT Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02689063 being conducted?

This trial has 2 study locations across Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Post Operative Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.